



Transplant Complications Working Party

Chair: Zinaida Perić

Secretary: Ivan Moiseev

GvHD subcom: Olaf Penack

Survivorship subcom: Hélène Schoemans

AI subcom: Alberto Mussetti

CAR-T comps subcom: Charlotte Graham

Early comps and regimen-related toxicities subcom: Ivan Moiseev

Publications in 2024

- Penack O. et al. **ECP versus ruxolitinib in steroid-refractory chronic GVHD**. Bone Marrow Transplant. 2024 Jan 6.
- Penack O. et al. **Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study**. J Immunother Cancer. 2024 Jan 9.
- Penack O. et al. **PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation**. Blood Cancer J. 2024 Mar 15.
- Penack O. et al. **ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?** Leukemia. 2024 Mar 27.
- Bos S. et al. **ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults**. Eur Respir J. 2024 Mar 28.
- Penack O. et al. **Management of complications of chimeric antigen receptor T-cell therapy**. Haematologica. 2024 May 30.
- Schoemans H. et al. **Patient engagement in hematopoietic stem cell transplantation and cell therapy**. Bone Marrow Transplant. 2024 Jun 18.
- Penack O. et al. **How risky is a second allogeneic stem cell transplantation?** Leukemia. 2024 Jun 25.
- Gjærde LK. et al. **Standardized translations of the Lee Chronic GvHD Symptom Scale to 12 European languages: an EU COST Action cGvHD Eurograft project**. Bone Marrow Transplant. 2024 Oct 10.
- Orti G. et al. **Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation**. Leukemia. 2024 Nov 19.
- Brijs J. et al. **Immune checkpoint inhibitors therapy for solid organ malignancies after allogeneic hematopoietic stem cell transplantation**. Bone Marrow Transplant. 2024 Dec 13.

Presentations at EBMT 2025

Oral Presentations

- **Drozd-Sokolowska J.** ICU organization after HCT (with IDWP)
- **Doglio M.** Incidence and characteristics of IEC-HLH (with GOCART)

Poster Presentations

- **Schultze-Florey C.** Practice patterns of SGLT2 inhibitor use

Manuscripts in Writing/Finalisation Phase

- **Bilinski J.** Fecal microbiota transplant for GvHD.
- **Damm F. & Schetelig J.** ChIP studies.
- **Durakovic N.** Graft rejection in haploSCT survey.
- **Gagelmann N.** Daratumumab for PRCA.
- **Penack O.** CAR-T cell outcomes in patients with comorbidities.
- **Penack O.** PTCy vs. ATG in matched related donor allo.
- **Perić Z.** Steroid refractory acute GvHD survey.
- **Piekarska A.** ATG in MSD allo-HSCT.
- **Pulanic D.** Chronic GvHD over time.
- **Salas MQ.** Outcomes of PTCy in elderly AML/MDS.
- **Salooja N.** Pregnancy outcomes among SCT survivors.
- **Schultze-Florey C.** Impact of BMI on CAR-T cell therapy.
- **Schultze-Florey C.** SGLT2 inhibitor survey.
- **Tomaszewska A.** Complications of CTX-based haploHCT.
- **Turki A.** Machine learning and GvHD.

Active Studies

- **Mekinian A.** Autoimmune complications of alloHCT.
- **Moiseev I.** Severity and response in TA-TMA.
- **Montoro J.** Lung transplantation after alloHCT.
- **Novak P.** Secondary HLH post alloHCT.
- **Salooja N. & Horgan C.** Management of passage from paediatric to adult centres (transition survey).
- **Dachy G.** TMA after CAR-T cell therapy.
- **Stoelzel F.** Pseudo-progression after CAR-T cell therapy.

Upcoming Studies

- **Avenoso D.** Late complications of VOD.
- **Desnica L.** GvHD and relapse.
- **Dreta B.** Eosinophilia after CAR-T cell therapy.
- **Schoemans H.** Survivorship projection in Europe.
- **Schick F & Penack O.** AI methods for prediction of NRM, OS and complications in alloHCT and CAR-T.